- Company
- AZ’s Sidapvia can be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Mar 29, 2024 05:53am
- The diabetes combination drug Sidapvia can now be prescribed in general hospitals in Korea. According to industry sources, AstraZeneca Korea's Sidapvia (dapagliflozin-sitagliptin), which is a combination of its SGLT-2 inhibitor ‘Forxiga’ and DPP-4 inhibitor ‘Januvia’, has passed the drug committees(DCs) of around 30 medical institutio
- Company
- Reimb of renal anemia drug in progress upon FDA approval
- by Nho, Byung Chul Mar 29, 2024 05:53am
- The discussions on the insurance reimbursement of tablet-type renal anemia drugs are expected to gain momentum. As Korea’s health authorities were eyeing whether to start pricing negotiations for Mitsubishi Tanabe Pharma’s Vadanem based on the FDA’s approval decision in the U.S. and pricing decision in Europe, the FDA approval is expec
- Company
- Samsung Bioepis makes 3rd investment in ADCs
- by Son, Hyung-Min Mar 28, 2024 05:52am
- Samsung Group, together with Samsung Bioepis, has made its third investment in companies discovering Antibody-Drug Conjugates (ADCs). Samsung Group plans to actively participate in new drug commercialization through acquiring the original technology as Samsung Biologics expands its CDMO facility for producing ADCs. Samsung Group announced on
- Company
- HK Inno.N speeds up clinical research on its NSCLC candidate
- by Nho, Byung Chul Mar 28, 2024 05:52am
- On the 27th, HK inno.N announced that it will present the non-clinical trial results of its next-generation allosteric EGFR-tyrosine kinase inhibitor ("EGFR-TKI") candidate through a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5 to 10 in the United States. e AACR is one of the
- Company
- New breast cancer drug ‘Truqap’ soon to land in KOR
- by Eo, Yun-Ho Mar 28, 2024 05:52am
- The AKT inhibitor 'Truqap' is likely to enter the Korean market. According to industry sources, AstraZeneca Korea has submitted an application for Truqap (capivasertib), which is used in combination with 'Faslodex (fulvestrant),' approval to the Ministry of Food and Drug Safety (MFDS), and is under review. The approval is expected to be
- Company
- AI-based liquid biopsy companies deliver tangible results
- by Son, Hyung-Min Mar 28, 2024 05:52am
- Domestic companies have started to deliver tangible results with their liquid biopsy technology. The early cancer diagnosis accuracy of GC Genome’s ai-CANCERCH and IMBdx’s CancerFind were found to be over 80%. EDGC's (Eone-Diagnomics Genome Center) test showed an 80% sensitivity in diagnosing colorectal cancer. Liquid biopsy detects disease
- Company
- Dt&CRO signs MOU with U.S. company Radyus Research
- by Nho, Byung Chul Mar 27, 2024 06:04am
- On the 25th, Dt&CRO announced that it had signed a memorandum of understanding (MOU) with Radyus Research, a U.S. clinical consulting organization. The MOU is expected to add momentum to the company’s full-cycle consulting service that is provided to domestic pharma and biotech companies that apply for Investigational New Drug (IND) or
- Company
- No news on Phesgo's reimb progress for 7 months
- by Eo, Yun-Ho Mar 27, 2024 06:04am
- The insurance reimbursement process for Phesgo, a drug that was expected to benefit from the preferential drug pricing system, is making little progress. No news has been heard on its progress for 7 months. Roche Korea’s Perjeta (pertuzumab+ trastuzumab), a subcutaneous injectable combination of the company’s Perjeta and Herceptin, pass
- Company
- Adtralza reimb drives biologics competition in atopy market
- by Eo, Yun-Ho Mar 26, 2024 06:30am
- Biopharmaceuticals face competition in the atopic dermatitis sector. According to industry sources, LEO Pharma’s Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13), is anticipated to launch with reimbursement starting in May. Adtralza is the second biologic
- Company
- Sam Chun Dang Pharm introduces Eylea biosimilar to Europe
- by Nho, Byung Chul Mar 26, 2024 06:30am
- Sam Chun Dang Pharm announced on the 25th an exclusive distribution agreement for the Eylea biosimilar with nine Western European countries (UK, Belgium, Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland). Under the agreement, Sam Chun Dang Pharm will receive 55% of the partnering company’s net sales, further strength
